Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does <italic>CDKN2A</italic> loss predict palbociclib benefit?</title><author><name sortKey="Gao, J" sort="Gao, J" uniqKey="Gao J" first="J." last="Gao">J. Gao</name><affiliation><nlm:aff id="af1-conc-22-e498">National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.;</nlm:aff></affiliation></author><author><name sortKey="Adams, R P" sort="Adams, R P" uniqKey="Adams R" first="R. P." last="Adams">R. P. Adams</name><affiliation><nlm:aff id="af2-conc-22-e498">Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, U.S.A.</nlm:aff></affiliation></author><author><name sortKey="Swain, S M" sort="Swain, S M" uniqKey="Swain S" first="S. M." last="Swain">S. M. Swain</name><affiliation><nlm:aff id="af2-conc-22-e498">Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, U.S.A.</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">26715889</idno><idno type="pmc">4687677</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687677</idno><idno type="RBID">PMC:4687677</idno><idno type="doi">10.3747/co.22.2700</idno><date when="2015">2015</date><idno type="wicri:Area/Pmc/Corpus">000155</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000155</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Does <italic>CDKN2A</italic> loss predict palbociclib benefit?</title><author><name sortKey="Gao, J" sort="Gao, J" uniqKey="Gao J" first="J." last="Gao">J. Gao</name><affiliation><nlm:aff id="af1-conc-22-e498">National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.;</nlm:aff></affiliation></author><author><name sortKey="Adams, R P" sort="Adams, R P" uniqKey="Adams R" first="R. P." last="Adams">R. P. Adams</name><affiliation><nlm:aff id="af2-conc-22-e498">Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, U.S.A.</nlm:aff></affiliation></author><author><name sortKey="Swain, S M" sort="Swain, S M" uniqKey="Swain S" first="S. M." last="Swain">S. M. Swain</name><affiliation><nlm:aff id="af2-conc-22-e498">Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, U.S.A.</nlm:aff></affiliation></author></analytic><series><title level="j">Current Oncology</title><idno type="ISSN">1198-0052</idno><idno type="eISSN">1718-7729</idno><imprint><date when="2015">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor–positive, <sc>her</sc>2-negative breast cancer. Patients with loss of <italic>CDKN2A</italic> (<italic>p16</italic>), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor– positive, <sc>her</sc>2-negative breast cancer with <italic>CDKN2A</italic> loss who experienced a clinical response to palbociclib.</p></div></front></TEI><pmc article-type="case-report"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title-group><journal-title>Current Oncology</journal-title></journal-title-group><issn pub-type="ppub">1198-0052</issn><issn pub-type="epub">1718-7729</issn><publisher><publisher-name>Multimed Inc.</publisher-name><publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26715889</article-id><article-id pub-id-type="pmc">4687677</article-id><article-id pub-id-type="doi">10.3747/co.22.2700</article-id><article-id pub-id-type="publisher-id">conc-22-e498</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Does <italic>CDKN2A</italic> loss predict palbociclib benefit?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gao</surname><given-names>J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af1-conc-22-e498"><sup>*</sup></xref></contrib><contrib contrib-type="author"><name><surname>Adams</surname><given-names>R.P.</given-names></name><degrees>CRNP</degrees><xref ref-type="aff" rid="af2-conc-22-e498"><sup>†</sup></xref></contrib><contrib contrib-type="author"><name><surname>Swain</surname><given-names>S.M.</given-names></name><degrees>MD</degrees><xref ref-type="corresp" rid="c1-conc-22-e498"></xref><xref ref-type="aff" rid="af2-conc-22-e498"><sup>†</sup></xref></contrib><aff id="af1-conc-22-e498"><label>*</label>National Cancer Institute, National Institutes of Health, Bethesda, MD, U.S.A.;</aff></contrib-group><aff id="af2-conc-22-e498"><label>†</label>Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC, U.S.A.</aff><author-notes><corresp id="c1-conc-22-e498">Correspondence to: Sandra M. Swain, 110 Irving Street NW, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC 20010 U.S.A. E-mail: <email>sandra.m.swain@medstar.net</email></corresp></author-notes><pub-date pub-type="ppub"><month>12</month><year>2015</year></pub-date><volume>22</volume><issue>6</issue><fpage>e498</fpage><lpage>e501</lpage><permissions><copyright-statement>2015 Multimed Inc.</copyright-statement><copyright-year>2015</copyright-year></permissions><abstract><p>Palbociclib, an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6, was recently approved by the U.S. Food and Drug Administration in combination with letrozole for postmenopausal women with advanced hormone receptor–positive, <sc>her</sc>2-negative breast cancer. Patients with loss of <italic>CDKN2A</italic> (<italic>p16</italic>), an inherent negative regulator of cyclin-dependent kinases 4 and 6, were not separately studied because of the significant response of the patients selected based only on receptor status. Here, we report a patient with metastatic estrogen receptor– positive, <sc>her</sc>2-negative breast cancer with <italic>CDKN2A</italic> loss who experienced a clinical response to palbociclib.</p></abstract><kwd-group><kwd>Medical oncology</kwd><kwd>breast cancer</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000155 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000155 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.31. |  |